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Cystic fibrosis (CF) is an autosomal recessive disorder caused by
many types of genetic defects, including premature stop codons.
Gentamicin can suppress stop mutations in CF transmembrane con-
ducatnce regulator (CFTR) in vitro and in vivo, leading to improve-
ments in CFTR-dependent ion transport and protein localization to
the apical surface of respiratory epithelial cells. The primary objec-
tive of this study was to test whether nasally administered gentami-
cin or tobramycin could suppress premature stop mutations in CFTR,
resulting in full-length, functional protein. A secondary objective
was to obtain data to aid in the design of multicenter trials using
the nasal potential difference as a study endpoint. A multicenter
study was conducted in two cohorts of patients with CF, those
heterozygous for stop mutations in the CFTR gene and those with-
out nonsense mutations, to investigate the effects of both gentami-
cin and tobramycin administered over a 28-d period on sequential
nasal potential difference and airway cell immunofluorescence end-
points. Eleven patients with CF with stop mutations were enrolled
in a randomized, double-blinded, crossover fashion to receive each
drug, while 18 subjects with CF without stop mutations were ran-
domized 1:1 in a parallel fashion to receive one drug. After demon-
stration of drug delivery, neither aminoglycoside produced detect-
able changes in nasal ion transport or CFTR localization in brushed
cells from either study group. These results with first-generation
suppressive agents suggest the need for improved drug delivery
methods and/or more potent suppressors of nonsense mutations
to confer CFTR correction in subjects with CF heterozygous for
nonsense mutations. The study provides valuable information on
parameters of the nasal potential difference measurements for use
in future multicenter clinical trials.
Keywords: cystic fibrosis; nonsense mutations; chloride secretion; nasal
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Nonsense mutations are the result of single base pair substitu-
tions that produce in-frame stop codons (UGA, UAA, UAG)
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CLINICAL RELEVANCE
This study demonstrates that not all premature stop muta-
tions are equally sensitive to suppression in vivo, and will
help researchers design clinical trials to detect CFTR
activity.
within an exon and mRNA transcript, leading to premature
truncation of protein translation (1). The resultant protein gener-
ally has reduced or absent function, and transcripts possessing
premature stop mutations are inherently unstable (2–6). To-
gether, these abnormalities elicit a profound defect in protein
biosynthesis, and are frequently found in diseases with a direct
(cystic fibrosis [CF], Hurler’s syndrome, Duchenne’s muscular
dystrophy) or indirect contribution (mutations in the P53 gene
or breast cancer susceptibility genes) from the affected gene
(7–13).
Methods to improve the function of genes with premature
termination codons have the potential for broad application to
a variety of genetic disorders. In CF, premature stop codons are
found in approximately 10% of the general population with CF
(8–10). Affected individuals of certain ethnicities, such as those
of Ashkenazi Jewish descent, have a much higher incidence of
premature stop mutations in CF transmembrane conductance
regulator (CFTR) ( 85% harbor mutations of this class). These
mutations in CFTR are generally predictive of a severe CF phe-
notype, particularly in regards to pancreatic insufficiency (8).
Aminoglycoside antibiotics have been shown to interact with
the small ribosomal RNA subunit (18S) in eukaryotic cells, alter-
ing normal ribosomal proofreading during protein translation
(11, 12, 14–18). Occasionally, this interaction leads to the binding
of a near cognate amino-acyl tRNA at the premature stop codon,
inserting an erroneous amino acid and allowing normal transla-
tion to progress to the end of the mRNA transcript. By this
mechanism, suppression of premature stop mutations can lead
to the production of full-length and functional protein. This
effect has been demonstrated in a variety of models, from heter-
ologous expression and cell-free systems, to cell lines and pri-
mary cells from patients possessing nonsense mutations, and
recently in mouse models of muscular dystrophy and CF (11,
14, 15, 19–22). The specificity of the approach is attributable to
greater stop codon fidelity at the authentic (3) end of mRNA
(secondary to redundant termination signals). Gentamicin is
a clinically approved antimicrobial that exhibits suppressive
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activity in certain models, and these preclinical findings have led
to exploratory clinical trials evaluating both systemic and topical
administration in subjects with stop mutations (12, 22–24). Re-
cently, Wilschanski and colleagues in an Israeli trial provided
compelling evidence that topical gentamicin, when applied di-
rectly in drop form to the nasal mucosa of CF patients possessing
premature stop mutations, conferred improvements in CFTR-
dependent ion transport (24). Immunocytochemical analysis
confirmed localization of full-length CFTR protein to the airway
cell surface specifically in treated subjects with nonsense alleles.
The current study was designed to test if gentamicin or tobra-
mycin (a potent antimicrobial with limited effects on stop codons
in vitro), when administered as a nasal spray, could activate stop
mutations in CFTR in patients with CF heterozygous for a wide
array of premature termination mutations, as compared to con-
trol patients with CF without stop mutations. Another objective
of this study was to gain longitudinal nasal potential difference
(nasal PD) data to more accurately estimate the multicenter




All human studies were approved by the institutional review boards
and the general clinical research center scientific advisory committees
within the participating centers. Informed consent was obtained from
all participants before initiating the protocol. Inclusion criteria included:
age greater than 7 yr, diagnosis of CF based on two positive sweat Cl-
tests and the identification of two causative mutations in CFTR, absence
of systemic antibiotic use for four weeks prior to initiation of the
protocol, and no use of topical nasal aminoglycosides. Study subjects
treated with inhaled tobramycin therapy (TOBI) were instructed to
wear nose clips during tobramycin nebulization. Subjects who used
other topical nasal therapies (e.g., nasal steroids) were instructed to
continue their use for the duration of the protocol to minimize nasal
mucosal edema and inflammation. All subjects were in stable health
as judged by their CF care physician. The participating study sites and
number of subjects enrolled (in parentheses) included The University
of Alabama at Birmingham (12), The University of North Carolina (3),
The Johns’ Hopkins University (4), The University of Cincinnati (3),
the University of Washington (6), and Stanford University (1). Detailed
demographic information is included in Table 1.
Before the protocol, limited studies were performed in six patients
with CF to confirm study drug delivery by the standardized nasal spray
device (Healthcare Logistics, Circleville, OH). For these studies, mean
baseline PD measurements were tabulated from measurements at 1, 2,
and 3 cm under the inferior turbinate (Ringer’s perfusate, which was
stopped upon contact with the nasal mucosa). The nasal catheter was
removed, and subjects were then dosed with two sprays of Ringer’s solution
(100 l/spray, or 200 l total). The nasal PD measurements were repeated,
and then the study patients were dosed with two sprays of Ringer’s 
amiloride (100 M). Basal PD measurements were repeated a third
time, and the % inhibition of the initial mean PD was then determined
for the mean PDs obtained after Ringer’s and Ringer’s  amiloride
application. Paired t tests were used to compare the PD values in the
presence and absence of amiloride. A P value of  0.05 was considered
statistically significant.
Subjects with CF possessing stop mutations were treated for 2 wk
with nasally administered gentamicin sulfate and tobramycin sulfate
(0.3 percent; Bausch and Lomb ophthalmic preparations, Rochester,
NY) in a randomized, double-blind crossover format (Figure 1, top).
Subjects received two sprays of study drug to each nostril three times
daily for 2 wk. Study drug was administered with a standardized nasal
spray device that provided 100 l per spray (200 l per application
per nostril), yielding a total daily dose of 1,800 g of gentamicin or
tobramycin (in 600 l) to each nostril per day. Subjects were instructed
in use of the nasal spray device, and asked to lie with the treated side
dependent for 3–5 min after administration to facilitate drug delivery
under the inferior turbinate. One-week-supply bottles of study drug
TABLE 1. GENOTYPE AND DEMOGRAPHIC INFORMATION OF
STUDY SUBJECTS
Age (yr) Sex Genotype

































Mean yr (SD) 23.2 (12.3) M:F 9:9 F508/F508: 14:18
were provided (with 25% overfill) at Days 0, 7, 42, and 49 for the
premature stop group, and at Days 0 and 7 for the control group. Based
on dispensed and returned bottle weights, the estimated compliance
with study drug for the premature stop group was 72.44% (range,
62.08–108.83%) and 62.87% (range, 49.58–78.99%) for the control
group. To assess for mucosal damage due to study drug application,
the nasal mucosa was visually inspected at each study visit for mucosal
integrity, erythema, swelling, bleeding, and friability (score range 0–4
for each parameter). The washout period between aminoglycosides was
Figure 1. Outline of study protocol. Each premature stop subject was
treated with both study drugs (gentamicin, tobramycin) for 2 wk, with
a 1-mo washout between administrations (random order of study drug
treatment). Each control subject was treated with either gentamicin or
tobramycin (random selection) for a single 2-wk period. Arrows: nasal
PD measurements; * nasal curettage.
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Figure 2. Effects of 100 M amiloride in Ringer’s solution on
baseline PD in patients with CF. (A ) Percent inhibition of basal
nasal PD after two sprays of Ringer’s compared with Ringer’s
 amiloride (100 M) in six subjects with CF (mean of 1, 2,
and 3 cm values for two nostrils each). *P  0.001 for Ringer’s
compared with Ringer’s  amiloride conditions. (B ) Effects of
Ringer’s and Ringer’s  amiloride spray on basal PD from one
subject with CF (single nostril). Left: Basal PD at 1, 2, 3 cm as
noted. Middle: Basal PD after two sprays of Ringer’s. Right:
Basal PD after two sprays of Ringer’s  amiloride. Scale is as
noted on tracing (mV), with upward deflections polarizing
(more negative).
a minimum of 28 d. Nasal PD measurements were performed on Days
0, 7, 14, 28, 42, 49, 56, and 70 of the protocol. For each study drug
period, the primary endpoint was an overall improvement in the nasal
ion transport from baseline (Day 0) over the 14-d study drug administra-
tion period as well as the through the washout period at Day 28. Nasal
curettage was performed after the nasal PD on Days 14, 28, 56, and
70. The secondary endpoint was detection of full-length CFTR in pri-
mary nasal cells by immunocytochemical staining over the 28-d study
drug period. CF control subjects without stop mutations underwent a
shortened protocol in which they were randomly assigned to receive
2 wk of either gentamicin or tobramycin (Figure 1, bottom). Nasal
potential difference measurements were performed in control subjects
on Days 0, 7, 14, and 28, and nasal curettage on Days 14 and 28.
All safety data was reviewed by an independent external Data Safety
Monitoring Board on an ongoing basis.
Nasal PD Measurements
The nasal PD is a bioelectric assay of CFTR-dependent ion transport
that has been used in a variety of protocols designed to detect CFTR
function. The assay is based on the description by Knowles and col-
leagues (25), and -agonist–stimulated Cl- conductance (in “0” [Cl-] 
amiloride) is the most sensitive measure of CFTR activity within the
nasal PD protocol. All Therapeutic Development Network (TDN)
study sites were certified for the assay using standard operating proce-
dures (SOPs) developed for multicenter studies (available on request
from the CF-TDN Coordinating Center at the University of Washington).
Solution #1 included Ringers solution, Solution #2 included Ringers 
100 M amiloride, Solution #3 included 0 [Cl-]  amiloride, Solution
#4 included 0 [Cl-]  amiloride  isoproterenol (10 M), and Solution
#5 was identical to solution #4  10 M ATP. Nasal PDs performed
at the University of Alabama at Birmingham were based on a similar
protocol developed before availability of the SOP. Differences in the
UAB protocol compared with the TDN protocol included (1) use of low
chloride (6 mMol) solution rather than a 0-mMol chloride solution, (2)
2-min perfusion times with Ringer’s solution plus amiloride (100 Mol)
and low [Cl-] plus amiloride instead of 3-min perfusions for both conditions,
and (3) absence of ATP perfusion (10 Mol) at the end of the measure-
ment. All nasal PD tracings were scored independently at the University of
North Carolina at Chapel Hill Nasal Potential Difference Interpretative
Center in a blinded fashion.
Nasal Curettage and Immunocytochemistry
The nasal cell procurement, staining, and scoring methodology have
previously been validated (24). Briefly, nasal cells were obtained from
study subjects using the Rhinoprobe nasal curettage (Arlington Sci-
ences, Springville, UT) after the completion of the nasal PD. Cells were
gently scraped from the inferomedial region of the inferior turbinate
(i.e., medial to the site of the nasal PD measurement) under direct
visualization and spread directly onto glass slides (Fisher Scientific,
Pittsburgh, PA). Slides were placed immediately in iced methanol
(HPLC grade; Fisher Scientific) for 10 min to fix and dehydrate cells.
The slides were then removed from methanol and air dried, placed
in styrofoam mailers, and sealed within an airtight container with an
accompanying humidity sponge (Control Company, Friendswood, TX).
The containers were then sent to the University of Alabama at Bir-
mingham Cystic Fibrosis Research Center for final processing and im-
munofluorescence scoring. A minimum of two slides per subject were
obtained to allow for appropriate internal antibody controls.
Before testing, cells were rehydrated with PBS (5 min) and blocked
with preimmune mouse serum for 20 min. The primary antibody (mouse
monoclonal anti-CFTR 24-1, directed to the carboxy terminal four amino
acids of full-length CFTR) was applied at a dilution of 1:100 for 2 h.
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Figure 3. Examples of normal (top) and CF (bottom)
nasal PD tracings. The x-axis is time (min) as de-
scribed, and the y-axis is PD (mV, upward is polariz-
ing). The normal phenotype includes a lower (less
polarized) baseline PD in Solution #1, a small depo-
larizing change in PD after amiloride perfusion (Solu-
tion #2), and a repolarizing PD after perfusion with
0 [Cl-] and 0 [Cl-]  isoproterenol (Solutions #3
and #4—continued presence of amiloride). The CF
phenotype includes a higher (more polarized) base-
line PD, a large depolarizing change in PD after
amiloride perfusion, and absent repolarization after
perfusion with 0 [Cl-] and 0 [Cl-]  isoproterenol.
ATP-stimulated PD (Solution #5, reflecting stimula-
tion of Calcium Activated Cl- Conductance) is re-
tained in normal subjects and in subjects with CF.
Slides were then washed three times in PBS, and incubated with second-
ary antibody (Goat anti-mouse IgG, AlexaFluor 596; Molecular Probes,
Portland, OR) for 1 h. Nuclei were identified by DAPI staining. Cells
were imaged on a digital confocal fluorescent microscope, and images
captured with IPLab Spectrum software (Scanalytics Inc., BD Biosci-
ences Bioimaging, Rockville, MD) (24). All samples were analyzed in
a blinded fashion by a single investigator. CFTR staining was classified
as (1 ) absent, (2 ) perinuclear, or (3 ) cytoplasmic and surface. At least
25 cells in two separate areas of each slide were evaluated and scored
(50 cells scored per slide).
Statistical Analysis
The parameters examined in this trial included (1 ) the baseline PD,
Table 2, (2 ) the % change in PD after amiloride perfusion (in Ringer’s,
Solution #2, Table 3), and (3 ) the total CFTR-dependent Cl- secretory
response (“TCS,” or change in PD from end of Solution #2 to end of
Solution #4 perfusion, Table 4). Analyses were performed as follows:
comparisons between groups (gentamicin-treated control subjects ver-
sus tobramycin-treated control subjects; premature stop group during
gentamicin treatment versus all control subjects; premature stop group
during tobramycin treatment versus all control subjects) and across the
four time periods (before 0 d, 7 d, 14 d, and after 28 d) were performed
using models containing group, time, and group by time interaction
terms; in addition, comparisons across the four time periods were per-
formed separately within each group (all control subjects, premature
stop group during gentamicin, and premature stop group during tobra-
mycin). These comparisons were performed using change from pretreat-
ment values (Day 7  Pre, Day 14  Pre, and Post  Pre) in place of
the actual values at each of the four time periods. All comparisons
TABLE 2. RESTING OR BASELINE NASAL PD
Premature Stop Group: Premature Stop Group: Control Group: Gentamicin
Day of Dosing Gentamicin Tobramycin and Tobramycin
D01 “pre” values 36.18 (17.16) 37.73 (10.87) 42.09 (10.12)
Day 07 (D07–D01) 2.43 (16.89) 3.48 (6.35) 6.40 (14.17)
Day 14 (D14–D01) 2.27 (16.09) 0.12 (9.44) 2.19 (18.21)
Post-values (D28–D01) 4.30 (16.51) 1.45 (9.10) 3.88 (14.12)
Definition of abbreviation: PD, potential difference.
Change in PD from pretreatment in premature stop subjects during gentamicin and tobramycin treatment, and in control
subjects during treatment (with either aminoglycoside). Values in the “Day 01 pretreatment” row are the actual mean resting PD
(	 SD). Values below are changes from the Day 01 value (average values of both nostrils per subject). Day 07 and Day 14 are
“on treatment.” Positive changes in PD reflect improvements in CFTR function.
were performed using mixed-models repeated measures analysis of
variance, assuming a first-order autoregressive covariance matrix.
Tukey’s multiple comparisons test was then used to determine which
specific pairs of means were significantly different. Results from the
study are based on mean values of both nostrils per subject per nasal
PD session. Additional analysis presented in this paper (examining
inter- and intrasubject variability of the Cl- secretory response, Tables
5–7) included (1 ) averaged responses (average of both nostrils per
subject per session) and (2 ) “best” response (most polarizing response
from either nostril during each nasal PD session). Aggregate data analy-
sis of left right nostril comparisons and repeatability (between Days 0
and 28) comparing all sites, the TDN sites (without UAB), and the
UAB site (without TDN sites) are also included (Tables 8 and 9).
Analyses were performed using SAS software (version 9.1; SAS Insti-
tute Inc., Cary, NC). All statistical tests were two-sided and were per-
formed at a 5% significance level (i.e., 
  0.05).
RESULTS
Assessment of Drug Delivery
Figure 1 provides a summary of the clinical protocol (discussed
in detail in the following section), and Figure 2 summarizes pre-
study analyses of drug delivery. To ensure that topical applica-
tion of drug reached the region of the nasal mucosa assayed
during the nasal PD measurement, experiments to confirm drug
delivery by the spray bottle were performed in subjects with
CF before initiating the clinical trial. All measurements were
performed at one site (UAB). Nasal PD measurements were
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TABLE 3. PERCENT CHANGE IN NASAL PD AFTER AMILORIDE
Premature Stop Group: Premature Stop Group: Control Group: Gentamicin
Day of Study Gentamicin* Tobramycin† and Tobramycin
D01 “pre” values 40.20% (18.26) 45.26% (17.81) 42.06% (12.57)
Day 07 (D07–D01) 5.18 (15.82) 0.31 (8.89) 8.90 (13.71)
Day 14 (D14–D01) 5.35 (18.62) 1.30 (13.70) 5.33 (16.16)
Post-values (D28–D01) 1.24 (20.31) 4.01 (11.08) 5.51 (15.61)
Definition of abbreviation: PD, potential difference.
Change in PD from pretreatment in premature stop subjects during gentamicin and tobramycin treatment, and in control
subjects during treatment (with either aminoglycoside). Values in the “Day 01 pretreatment” row are the mean % change in PD
after amiloride (	 SD). Values below are changes from the Day 01 value (average values of both nostrils per subject). Day 07
and Day 14 are “on treatment.” Reduced changes in PD reflect improvements in CFTR function.
* There is a significant group x day interaction for the averaged nostril results (P  0.02, groups  control subjects and premature
stop subjects on gentamicin). None of the individual pair-wise comparisons are significant.
† There is significant difference between groups for the averaged nostril results (P  0.05, groups  control subjects and
premature stop subjects on tobramycin). None of the individual pair-wise comparisons are significant.
performed (mean of 1.0, 2.0, and 3.0 cm under the inferior turbi-
nate) at baseline, after two sprays (200 l) of Ringer’s solution,
and after two sprays of 100 M amiloride in Ringer’s solution as
described in Materials and Methods. The perfusate (Ringer’s)
was stopped after contact with the nasal mucosa to ensure that
the dosed amiloride solution was not washed away by the PD
measurement. The effects of each application on the mean rest-
ing potential were then compared with pretreatment values for
each subject. Figure 2A summarizes data from six subjects with
CF undergoing measurements. Amiloride  Ringer’s solution
depolarized the resting potential difference by  50% compared
with Ringer’s solution alone (P  0.001). Figure 2B shows a
representative tracing from a single subject with CF before and
after dosing with amiloride solution by spray bottle delivery.
In general, measurements at multiple distances from the nasal
vestibule were depolarized in a similar manner, suggesting even
distribution of study drug after delivery. Together, these studies
confirmed that the spray delivery system was able to effectively
dose the region of the nasal mucosa accessed during nasal PD
measurements, and provided confidence that the drug delivery
system would provide reasonable distribution of study drug on
the nasal mucosa.
Figure 3 provides examples of normal (top) and CF (bottom)
nasal PD measurements. Upward deflections are polarizing. The
nasal PD findings in normal subjects include a less polarized
baseline PD in Ringer’s (Solution #1), a small change (depolariz-
ing) in PD after amiloride perfusion (Solution #2), and large
repolarization after establishment of a Cl- secretory gradient and
stimulation with isoproterenol (CFTR-dependent Cl- secretion;
Solutions #3 and #4). The traditional CF phenotype includes a
TABLE 4. CHANGE IN PD AFTER PERFUSION WITH 0 [Cl-]/AMILORIDE AND ISOPROTERENOL
(10 M) (SOLUTIONS #3 AND #4, OR TCS)
Premature Stop Group: Premature Stop Group: Control Group: Gentamicin
Day of study Gentamicin Tobramycin and Tobramycin
D01 “pre” values 3.97 (3.50) 3.89 (3.91) 2.99 (3.48)
Day 07 (D07–D01) 0.42 (4.21) 0.41 (4.42) 0.62 (3.81)
Day 14 (D14–D01) 2.88 (3.65) 1.59 (4.09) 0.11 (4.79)
Post-values (D28–D01) 1.50 (6.08) 1.43 (6.13) 0.26 (3.41)
Definition of abbreviations: PD, potential difference; TCS, total CFTR-dependent Cl secretion.
Change in PD from pretreatment in premature stop subjects during gentamicin and tobramycin treatment, and controls during
treatment (with either aminoglycoside). Values in the “Day 01 pretreatment” row are the mean change in PD after 0 [Cl-] and
10 M isoproterenol (Solutions #3 and #4 perfusion; 	 SD). Values below are changes from the Day 01 value (average values of
both nostrils per subject). Day 07 and Day 14 are “on treatment.” Negative changes in PD (polarizing) reflect improvements in
CFTR function.
high (polarizing) baseline PD, a large depolarizing response to
amiloride, and absent repolarization after establishment of a
Cl- secretory gradient and stimulation with isoproterenol. ATP-
stimulated Cl- secretion is enhanced in CF relative to normal
subjects (CFTR-independent Cl- secretion; Solution #5). The
parameters measured in this study included (1) the mean base-
line (or resting) PD, (2) the % change in PD after perfusion with
Solution #2 (amiloride), and (3) the change in CFTR-dependent
Cl- transport (change in PD from end of Solution #2 to the end
of Solution #4 perfusion).
Clinical Trial
A total of 30 subjects enrolled in the protocol, and 29 were able
to complete all components. One subject could not comply with
the nasal PD measurement at baseline and withdrew from the
protocol before initiating treatment. Eleven subjects with stop
mutations in CFTR and 18 subjects without stop mutations were
included in the final analysis. Table 1 summarizes CF genotypes.
In the premature stop group, six different premature stop muta-
tions in CFTR were represented (all heterozygous). The control
group included 14 of 18 subjects who were homozygous for
the F508 CFTR allele (and none of the mutations predicted
retained CFTR activity).
In general, the study interventions were well tolerated, with
infrequent adverse effects reported (mostly constitutional symp-
toms interpreted as unrelated to study drug or the nasal PD
measurements). There were no differences in nasal mucosa vi-
sual scores during the study to suggest mucosal injury due to
study drug application (either tobramycin or gentamicin). Tables
2–4 summarize the three parameters examined in the premature
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Figure 4. Examples of CFTR staining in human nasal
cells obtained by nasal curettage. Cells were derived
from subjects not treated with aminoglycosides. (A )
Three high-power fields (top panels and bottom left
panel) of nasal cells from a normal subject that ex-
hibit CFTR (red) and nuclear (blue) staining. Approxi-
mately 60% of cells stained positive for CFTR, with
the majority demonstrating either a cytoplasmic or
cytoplasmic/surface staining pattern (arrows). The
bottom right panel is a negative antibody control
(primary antibody omitted). (B ) Low-power fields
of nasal cells obtained from a normal subject, a
patient with CF homozygous for the F508 CFTR
mutation, and a subject with CF possessing a prema-
ture stop mutation (G542X/F508). The first two
panels demonstrate robust CFTR staining within the
cytoplasm and at the cell surface (normal subject).
The third panel shows perinuclear staining of CFTR
(F508/F508 subject). The final panel demon-
strates minimal CFTR staining (G542X/F508
subject).
stop and control groups. Based on mixed model analysis, no
interactions between groups over time were observed (baseline
PD, % change in PD after amiloride, CFTR-dependent Cl- secre-
tion). No statistically significant differences within groups (during
gentamicin or tobramycin treatment compared with off-treatment
periods) were observed in the resting PD (Table 2), the % change
in PD after amiloride perfusion (Table 3), or TCS (Table 4)
within either the premature stop group or the control CF group.
There were statistically significant differences in the % change
in PD after amiloride perfusion (Table 3) between the control
group and the premature stop group (discussed in Table 3). The
clinical significance of these differences is unclear, given that
they were not accompanied by improvements in other measures
of CFTR function (baseline PD or Cl- secretion, Tables 2 and
4, respectively), and no trends over treatment or time could be
identified. No other significant differences in nasal PD parame-
ters were seen comparing the premature stop group to the CF
control group during treatment with either aminoglycoside. Re-
peat analysis of “best responses” revealed similar results (see
detailed discussion in the following section).
Figure 4 provides examples of cytoplasmic and surface CFTR
staining of nasal cells brushed from normal control subjects,
perinuclear CFTR staining from a F508/F508 subject with
CF, and sparse staining from a subject with CF heterozygous
for a premature stop mutation (G542X/F508; all staining shown
was from cells isolated from subjects off of treatment). Approxi-
mately 50% of nasal curettage samples obtained during the pro-
tocol were adequate for subsequent analysis of CFTR localiza-
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tion. No consistent changes in CFTR staining were demonstrated
in premature stop subjects or control subjects with CF that could
be attributed to aminoglycoside treatment.
Analysis of Aggregate Nasal PD Data
As CFTR-dependent Cl- secretion has been shown to be the
most sensitive marker of CFTR activity and this measurement
displayed the least variability within our study (Tables 2–4), we
limited subsequent data analysis to this nasal PD parameter.
Tables 5–9 summarize nasal PD data obtained from subjects
with CF off of study drug treatment (change in TCS between
Day 0 and Day 28 for all subjects [premature stop and control
groups analyzed together]). Table 5 summarizes descriptive sta-
tistics for Cl- secretion, analyzing the data based on “average
responses” (from two nostrils for each subject, providing one
measurement/subject/d) and “best responses” (strongest Cl-
secretory response from either nostril, providing one measure-
ment/subject/d). While the variability in the 28-d change is
greater for the “best” nostril as compared to the average of the
two nostril measures, the best nostril results may be more likely
to show a treatment effect in the setting of an efficacious drug.
Using estimates from Table 5, Table 6 summarizes power calcula-
tions to detect various differences in Cl- secretion within a study
group (change in TCS), and Table 7 summarizes similar calcula-
tions to detect differences in Cl- secretion between two study
groups (80% power, 
  0.05). Thus, a sample size of 11 patients
has 80% power to detect a 4-mV or greater change in PD over
28 d (within-group improvement in nasal Cl- secretion based on
averaging the nostrils), and a similar sample size would be able
to detect a 5-mV or greater improvement based on the best
nostril response. Based on the total number of subjects enrolled
(premature stop group and controls), the current study had ade-
quate power to detect a treatment effect of 4.72 mV for between-
group comparisons (80% power, 
  0.05). Sample sizes are
approximately doubled for performing between-group compari-
sons. Importantly, the response based on averaging the nostrils
is less variable for within-group comparisons, but the best nostril
response elicits the greatest (most sensitive) treatment effect
within a single group. This should be considered when choosing
the primary analysis method to base future sample size
calculations.
Additional analyses assessing variability of the aggregate data
are included in Tables 8 and 9, and in Figures 5 and 6. Compari-
sons of left and right nostril responses (TCS) for the entire study
group, the TDN sites only (UAB data omitted) and the UAB
site (TDN data omitted) are included in Table 8. Left compared
with right nostril values for each subject differed by approxi-
mately 1 mV in all analyses, and the least variability was seen
for mean values of the left and right nostrils per subject. The TCS
measurement from the TDN sites was generally less depolarized
than the UAB data, likely reflecting the influence of the shorter
amiloride exposure (Solution #2, 3 min for TDN sites versus 2
TABLE 5. DESCRIPTIVE STATISTICS FOR ALL 29 SUBJECTS
Average of Left and Right Best of Left and Right Nostrils





Difference between pretreatment (Day 0) and Day 28 measurements (total
CFTR-dependent Cl secretion [end of Solution #2 through end of Solution #4],
all obtained off study drug).
TABLE 6. REQUIRED SAMPLE SIZES (TOTAL NUMBER OF
SUBJECTS) TO OBSERVE A WITHIN-GROUP EFFECT, 80%
POWER,   0.05, BY INCREASING TREATMENT EFFECT
Average of Left and Right Best of Left and Right
Treatment Effect Nostrils (per subject) Nostrils (per subject)
1 mV 144 230
2 mV 38 59
3 mV 18 28
4 mV 11 17
5 mV 8 12
min for the UAB site) or potentially differences in the content
of the low [Cl-] solution (zero [Cl-] for the TDN sites, and 6 mMol
for the UAB site). Figure 5 demonstrates modest correlation of
left and right nostril responses within subjects with CF for the
TCS measures (r  0.2433). Table 9 summarizes repeatability
of the TCS responses between Days 0 and 28 for all sites, the
TDN sites only, and the UAB site only (mean of left and right
nostrils per subject for each measurement); and Figure 6 summa-
rizes repeatability for all study sites (mean TCS values per sub-
ject). Again, the TDN sites displayed less depolarization com-
pared with the UAB (non-TDN) site, and the repeatability of
TCS measurements off study drugs was modest (r  0.244).
These data provide support for the use of standardized proce-
dures when performing the nasal PD as part of multicenter trials,
as the mean values from the UAB site differed from the TDN
sites, and the standard deviations of the UAB data was slightly
higher than that of the cumulative data obtained from the TDN
sites (using standardized procedures among all TDN study sites).
DISCUSSION
The goal of the current study was to examine whether treatment
with nasally administered aminoglycosides was associated with
improvement in nasal ion transport or full-length CFTR detec-
tion in airway cells of subjects with CF who were heterozygous
for a variety of different CFTR stop mutations. Our results
indicate that topical treatment with gentamicin or tobramycin
was not associated with detectable improvements in airway Na
transport or Cl- secretion. In addition, no differences were ob-
served in CFTR immunocytochemical studies of nasal cells ob-
tained from subjects before and during aminoglycoside treatment.
Our findings are in agreement with recent disparate reports
from Phase II studies examining the effects of the oral stop codon
suppressive agent PTC124 on nasal PD measures in American
compared with Israeli populations with CF harboring premature
stop mutations (26, 27). Our results also contrast with those
recently published by Wilschanski and colleagues, which clearly
demonstrated that topical gentamicin had significant positive
effects on ion transport (both Cl- secretion and Na absorption)
TABLE 7. REQUIRED SAMPLE SIZES (TOTAL NUMBER OF
SUBJECTS TO BE RANDOMIZED 1:1 TO EACH GROUP) TO
OBSERVE A BETWEEN-GROUP EFFECT, 80% POWER,
  0.05, BY INCREASING TREATMENT EFFECT
Average of Left and Right Best of Left and Right
Treatment Effect Nostrils (per subject) Nostrils (per subject)
1 mV 284 458
2 mV 72 115
3 mV 33 52
4 mV 19 30
5 mV 13 20
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TABLE 8. COMPARISON OF TCS VALUES FROM LEFT, RIGHT, MEAN, AND BEST NOSTRIL
RESPONSES (DAYS 0 AND 28 COMBINED) FOR ALL SITES, THE TDN SITES (UAB OMITTED,
n  17), AND THE UAB SITE (TDN SITES OMITTED, n  12)
Mean (Left and Right Best of Left and Right
Left Right Nostrils) Nostrils
Mean all sites 4.27 (4.43) 3.27 (4.57) 3.75 (3.54) 1.63 (3.92)
Mean TDN 2.99 (3.90) 2.18 (3.79) 2.58 (2.97) 0.73 (3.54)
Mean UAB 5.93 (4.56)† 4.64 (5.11)* 5.23 (3.68)* 2.72 (4.14)†
Definition of abbreviations: TDN, Therapeutic Development Network; UAB, University of Alabama at Birmingham.
Individual measurements were from the mean of left and right nostril per subject. The data are shown as the mean (	 SD).
* P  0.03 compared with TDN sites.
† P  0.01 compared with TDN sites.
as measured by the nasal PD, and accompanying improvements
in CFTR localization in nasal mucosal cells (24). Important dif-
ferences between the two trials likely account for the disparate
results. First, the group reported by Wilschanski and colleagues
was more homogenous. The majority of premature stop subjects
were homozygous for stop mutations (n  11/19), and all pos-
sessed at least one copy of the W1282X CFTR mutation. In
contrast, no subject in our study had two copies of premature
stop mutations, and only 1 of 11 subjects carried the W1282X
CFTR mutation. Subjects possessing two different premature
stop alleles might be predicted to recover more full-length, func-
tional CFTR protein with a given dose of aminoglycosides than
subjects carrying a single stop allele. Furthermore, in vitro studies
completed in our laboratory have demonstrated that W1282X
CFTR can retain partial function that is enhanced after stop
codon suppression (28). Thus, increased activity of W1282X
CFTR might be predicted in the context of higher expression
levels. Consistent with these results, a recent report by Shushi
and colleagues indicated that many of the CF subjects who failed
to respond to gentamicin treatment in their previous trial had
severely reduced levels of nonsense transcripts (29). Treatment
with an inhibitor of nonsense-mediated decay (NMD) restored
transcript levels and suppression by gentamicin in vitro. The
authors hypothesized that NMD may act as a genetic modifier
in this context. Thus, genetic differences in NMD between the
Israeli and American populations with CF may account in part
for differences in treatment effects (particularly in the context
of the W1282X CFTR mutation).
Other systematic differences in the studies may account for
the disparate results. The methods of drug delivery used in the
two studies were different, and it is plausible that delivery of
study drug by single drops produced higher local concentrations
of aminoglycoside than the spray system used in this trial (total
daily nasal dose of 900 g in Wilschanski’s study compared with
1,800 g in the current study) (24). Finally, the study in Israel
was conducted at a single center, a feature that might be expected
TABLE 9. REPEATABILITY OF TCS MEASURES FROM ALL CF
SUBJECTS, DAY 0 TO DAY 28 FOR ALL SITES, THE TDN
SITES (UAB OMITTED, n  17), AND THE UAB SITE
(TDN SITES OMITTED, n  12)
Mean (Left and Right) Mean (Left and Right)
Day 0 Day 28
Mean all sites 3.51 (3.54) 4.01 (3.56)
Mean TDN 2.45 (3.14) 2.71 (2.87)
Mean UAB 4.81 (3.66)* 5.68 (3.75)†
For definition of abbreviations, see Table 8.
Individual measurements were from the mean of left and right nostril per
subject. The data are shown as the mean (	 SD).
to limit the variability of the nasal PD measurement compared
with the inclusion of multiple sites in this study. While standard-
ized procedures were developed before initiating the study at
the TDN sites, the variability of data for all sites (premature stop
subjects: standard deviation for TCS  4.27, n  22 measurements—
single nostril values) and for the TDN sites alone (standard
deviation  3.13, n  12 measurements) was higher than those
reported by Wilschanski and colleagues (23, 24). These findings
highlight some of the difficulties in adapting the nasal PD assay
for use at multiple different institutions (30).
The four most common stop mutations (G542X, R553X,
R1162X, W1282X CFTR) all contain a UGA codon, and all have
been shown to be suppressed by aminoglycoside treatment in
vitro using heterologous expression systems. The less common
stop mutations found in our study subjects (E60X, Y1092X) are
produced by other codons (UAG or UAA, respectively) that
are frequently less sensitive to suppression than the UGA codon
(20). Thus, nucleotide differences seen in stop codons possessed
by subjects within our study group may also have contributed
to a reduced treatment effect.
Nasal cell immunocytochemistry did not demonstrate consis-
tent improvements in CFTR localization in treated premature
stop subjects compared with control subjects. This also differs
the previously published results (24). The similarity of the CFTR
detection protocols suggest that differences in the two study
populations (in terms of stop codons represented, number of
patients heterozygous versus homozygous for stop mutations,
or other population differences) or in the drug delivery method
contributed to the different study results.
Several recent reports have used the nasal PD assay in
multicenter studies, and have highlighted issues that can contrib-
ute to inter-site variability and the capacity to detect treatment
effects (30–32). A recent report was able to demonstrate the posi-
tive effect of warming of solutions on isoproterenol-stimulated Cl-
transport, including 32 normal subjects studied at four separate
institutions (32). No studies, however, have demonstrated im-
provements in nasal PD measures in patients with CF using a
multicenter study design. The nasal PD data obtained during
this protocol provides a large dataset derived from multiple
institutions in patients with CF with complete genotype informa-
tion. Review of the data indicates that the number of study
subjects needed for recruitment for future trials designed to
improve nasal ion transport is dependent not only on the treat-
ment effect size and variability, but by the method of data analy-
sis. The choice between using the average of individual nostrils
versus the “best” nostril should perhaps be made more on biolog-
ical proof of concept than statistical grounds. If any nostril is
shown to have significant response and this is thought to be
clinically relevant, then an argument for using the best nostril
for analysis could be made. It would be most thorough, however,
to perform the analysis using both approaches, given their possible
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Figure 5. Left versus right nostril TCS comparisons
versus each study subject with CF (n  29, Days 0
and 28 combined). The x-axis is left nostril values,
and the y-axis is right nostril values (in mV) for each
study subject.
disparity. A 5-mV change in PD has previously been shown to
be highly specific to detect CFTR-dependent Cl- transport in
subjects with CF (22), and only 2 of 158 “averaged responses”
(1.27%), 8 of 158 “best responses” (5.1%), and 8 of 318 (2.5%)
from “all responses” were  5 mV (polarizing) throughout
the entire trial. Based on these findings, analysis of results from
multicenter trials should seek to reduce variability by providing
single measurements per subject per nasal PD recording. Analy-
sis of “averaged responses” are more specific and less likely to
contribute to Type I errors, whereas “best responses” may improve
sensitivity to detect low-level Cl- secretion. Importantly, all three
types of analysis of the current dataset failed to demonstrate
consistent treatment effects within or between study groups.
The aggregate data shown in Figures 5 and 6 and Tables 8
and 9 compare left versus right nostril values and repeatability
of mean TCS measurements (between Days 0 and 28) for all
study subjects (n  29), the subjects studied at TDN sites (n 
17), and the subjects studied at UAB (n  12). The TCS measures
from UAB differed from the TDN sites, likely representing
subtle methodologic differences in nasal PD performance be-
tween the UAB and TDN study groups. These findings highlight
the value of using standardized techniques and procedures when
performing the nasal PD as an outcome measure in multicenter
trials, and provide support for efforts to identify and assess
factors that contribute to inter- and intrasite variability of the
assay (such as nasal catheters, study subject interface, choice of
electrodes, etc.).
Figure 6. Repeat TCS measurements in study
subjects with CF (n  29, Days 0 and 28). The
x-axis is Day 0 values and the y-axis is Day 28
values (in mV, mean of left and right nostrils)
for each study subject.
In summary, the results of our studies indicate that nasally
administered aminoglycosides did not produce detectable im-
provements in CFTR function or localization in subjects hetero-
zygous for a variety of stop mutations within CFTR. Our results
suggest the need to identify more efficacious agents with a
broader spectrum of activity, improved systemic absorption, and
reduced toxicity before this approach can be successfully used
in a population with a diverse array of premature termination
codons. The results of this study will provide valuable informa-
tion to investigators planning multicenter trials of new therapeu-
tics that use the nasal PD as a biological efficacy endpoint.
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